IP Library Granted Patent US 10,550,087
Granted Patent B2
US 10,550,087 · App. 15/776,762 · Granted Feb 4, 2020

Process for the preparation of kinase inhibitors and intermediates thereof

Inventors: Jill Marie Sturdivant (Chapel Hill, NC); Mitchell A. deLong (Chapel Hill, NC); Gilles Chambournier (Ann Arbor, MI); Michael G. Pamment (Ann Arbor, MI); Victor Fedij (Ypsilanti, MI)
Assignee: Aerie Pharmaceuticals, Inc.
C07D217/02C07C69/78C07D249/18C07D277/14
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,550,087
App. No.
15/776,762
Granted
Feb 4, 2020
Kind
B2
Abstract

Described are processes for the synthesis of certain compounds, useful for treating diseases, e.g. eye disease, such as glaucoma and ocular hypertension, in a subject.

Claims (39)

1. A method for the synthesis of a compound of Formula (I):

or a pharmaceutically acceptable salt thereof; wherein A is cyclohexyl or phenyl, substituted with 0-3 substituents independently selected from alkyl, halogen, alkoxy, or cyano;

the method comprising

(a) reacting a compound of Formula (II), wherein PG is a nitrogen protecting group,

with 6-aminoisoquinoline to form a compound of Formula (III)

wherein A is cyclohexyl or phenyl, substituted with 0-3 substituents independently selected from alkyl, halogen, alkoxy, or cyano; and

(b) removing the nitrogen protecting group to form the compound of Formula (I);

further comprising:

(c) reacting a compound of Formula (IV),

wherein A is cyclohexyl or phenyl, substituted with 0-3 substituents independently selected from alkyl, halogen, alkoxy, or cyano; and T is a chiral auxiliary; with

wherein PG is a nitrogen protecting group;

to form a compound of Formula (V):

wherein A is cyclohexyl or phenyl, substituted with 0-3 substituents independently selected from alkyl, halogen, alkoxy, or cyano; and T is a chiral auxiliary; and

(d) removing the chiral auxiliary to form the compound of Formula (II).

2. The method of claim 1 , further comprising converting a compound of Formula (VIII):

wherein A is cyclohexyl or phenyl, substituted with 0-3 substituents independently selected from alkyl, halogen, alkoxy, or cyano; and R 1 is halogen, OR a , OC(O)R b , SR a , or SC(O)R b ; wherein R a is H, alkyl or aryl, and R b is alkyl or aryl;

to the compound of Formula (IV):

wherein A is cyclohexyl or phenyl, substituted with 0-3 substituents independently selected from alkyl, halogen, alkoxy, or cyano; and T is a chiral auxiliary.

3. The method of claim 2 , wherein the compound of Formula (II) is synthesized by a method comprising:

(a) reacting

with a compound of Formula (VI),

wherein A is cyclohexyl or phenyl, substituted with 0-3 substituents independently selected from alkyl, halogen, alkoxy, or cyano;

to form a compound of formula (VII-a),

wherein A is cyclohexyl or phenyl, substituted with 0-3 substituents independently selected from alkyl, halogen, alkoxy, or cyano; and

(b) converting the compound of Formula (VII) into the compound of Formula (VIII).

4. The method of claim 1 , wherein T is

wherein

Z is S or O;

B is S or O;

R c is hydrogen, C 1-4 alkyl, or aryl; and

R d is C 1-4 alkyl, C 3-7 branched alkyl; arylalkyl or aryl.

5. The method of claim 4 , wherein T is

wherein

Z is S or O;

B is S or O;

R c is hydrogen or aryl; and

R d is C 1-4 alkyl, arylalkyl or aryl.

6. The method of claim 5 , wherein T is selected from:

7. The method of claim 6 , wherein T is

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 24, 2024
From: AERIE PHARMACEUTICALS, INC.
To: ALCON INC.
Reel/Frame 067822/0168 →
RELEASE OF SECURITY INTEREST Recorded Sep 5, 2019
From: DEERFIELD PRIVATE DESIGN FUND III, L.P.
To: AERIE PHARMACEUTICALS, INC.
Reel/Frame 050276/0807 →
SECURITY INTEREST Recorded Jul 23, 2018
From: AERIE PHARMACEUTICALS, INC.
To: DEERFIELD PRIVATE DESIGN FUND III, L.P.
Reel/Frame 046432/0307 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 18, 2018
From: STURDIVANT, JILL M.; DELONG, MITCHELL A.; CHAMBOURNIER, GILLES; PAMMENT, MICHAEL G.; FEDIJ, VICTOR
To: AERIE PHARMACEUTICALS, INC.
Reel/Frame 045849/0981 →
Continuity (1)
Related Publication 20180370919A1 · Dec 27, 2018
Cited By (1)
US 12,692,234